Oral & Maxillofacial Surgeons in Phoenix and Tempe Unveil Innovative New Website
October 18, 2018 11:00 ET | Oral & Facial Surgeons of Arizona
The doctors at Oral & Facial Surgeons of Arizona are opening the virtual doors on a comprehensive new website designed to provide a new resource for individuals looking for advanced treatment...
gmi 2018.png
U.S. Medical Marijuana Market worth over USD 8 billion by 2024: Global Market Insights, Inc.
September 17, 2018 06:15 ET | Global Market Insights, Inc
Sellbyville, Delaware, Sept. 17, 2018 (GLOBE NEWSWIRE) -- The U.S. Medical Marijuana Market is poised to surpass USD 8.0 billion by 2024; according to a new research study published by Global...
CURE Logo.png
CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement
September 05, 2018 08:57 ET | CURE Pharmaceutical
LOS ANGELES, Sept. 05, 2018 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC: CURR), (“CURE”), an innovative drug delivery and development company, today announced that it entered into a multi-year...
gmi 2018.png
Medical Marijuana Market worth over $55 billion by 2024: Global Market Insights, Inc.
August 22, 2018 07:00 ET | Global Market Insights, Inc
Sellbyville, Delaware, Aug. 22, 2018 (GLOBE NEWSWIRE) -- Global Medical Marijuana Market outlook is projected to surpass USD 55 billion by 2024, says a new Global Market Insights, Inc. report...
rhL
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)
April 09, 2018 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...
Rhizen Pharmaceuticals S.A. announces clinical data presentations for Tenalisib (RP6530) in R/R T-cell lymphoma at the upcoming 10th Annual T-Cell Lymphoma Forum in La Jolla, CA, USA
January 29, 2018 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated clinical data for Tenalisib (RP6530), the company’s highly selective and...
Rhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for RP6530 (tenalisib), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL)
December 09, 2017 08:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for...
Rhizen Pharmaceuticals S.A. announces clinical and preclinical data presentations at the upcoming 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, GA, USA
December 05, 2017 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that updated data for RP6530 (tenalisib), the Company’s highly selective and orally...
Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma
September 22, 2015 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...